You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke
SBC: TRANSLATIONAL SCIENCES INC Topic: 103Ischemic stroke is the second leading cause of death and disability worldwide. Tissue plasminogen activator (TPA), the only approved treatment for ischemic stroke, dissolves the culprit fibrin thrombus to restore blood flow and relieve the brain from ischemia. Unfortunately, after prolonged ischemia, TPA restores full blood flow in only 30% of patients and may cause serious or fatal complications; ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II
SBC: TRANSLATIONAL SCIENCES INC Topic: NHLBIThis SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting DNA damage response pathways for the treatment of advanced lung cancer
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 102ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
An H/F/X/Y Fast-MAS NMR Probe Particularly for Alzheimer's and Cancer Research
SBC: DOTY SCIENTIFIC, INC. Topic: 400An H/F/X/Y Fast-MAS NMR Probe Particularly for Alzheimer’s and Cancer Research AbstractMore than 20% of current drugs (and a much greater fraction of those in development) are fluorinated (including such block-busters as Prozac, Lipitor, and Ciprobay). Steady progress over the past decade has shown magic angle spinning (MAS) solid-state NMR (ssNMR) to be arguably the most powerful analytical too ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Clinical evaluation of a compliant, degradable ureteral stent to reduce patient pain and improve tolerability
SBC: ADVA-TEC, INC. Topic: 400PROJECT SUMMARY Kidney stones represent a significant health concern both domestically and worldwide, with incidence rates increasing over the past three decades due to the combination of dietary habits and sedentary lifestyle. Ureteral stents are an important tool to support kidney stone management, but for the past 50 years have not advanced beyond the traditional nondegradable single- or double ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide
SBC: FirstString Research, Inc Topic: 102PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Administrative Supplement to Promote Diversity in Research and Development Small Businesses
SBC: NEUROENE THERAPEUTICS INC Topic: NINDSAbstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Squashing the Scope Superbug: A Disposable System for ERCP that Saves Patients from Bacterial Cross-Contamination
SBC: ENDOTHEIA INC Topic: 300Project Summary/Abstract: The objective of this proposal is to create a new low-cost, disposable system that enables reliable, safe, standard endoscopes to replace expensive, customized duodenoscopes, which have recently been shown to cause infections at an alarming rate. Clinical significance comes from the fact that 40,000 patients per year will be infected by unclean duodeno- scopes, among the ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...
STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency